Literature DB >> 30485860

Clinicopathological Profiling of Lung Carcinoids with a Ki67 Index > 20.

Atsuko Kasajima1,2,3, Björn Konukiewitz4, Naomi Oka5,6, Hiroyoshi Suzuki6, Akira Sakurada7, Yoshinori Okada7, Toru Kameya8, Yuichi Ishikawa9, Hironobu Sasano5, Wilko Weichert4,10, Günter Klöppel4.   

Abstract

The clinicopathological features of lung neuroendocrine neoplasms (NEN) with a high proliferative index at the border area between atypical carcinoid and neuroendocrine carcinoma have not been investigated so far. The aim of this study was, therefore, to search for lung NENs which are well differentiated but show Ki67 values that overlap with those of poorly differentiated (PD)-NENs. Resected lung NENs from 244 Japanese patients were reviewed, and Ki67 indices were assessed in all tumors. The data were then correlated to clinicopathological parameters and patient outcome. Among 59 (24%) well-differentiated (WD)-NENs and 185 (76%) lung PD-NENs, 7 were defined as WD-NENs with Ki67 indices > 20%. The Ki67 indices of these tumors (mean 29%, range 24-36) were significantly lower than those of PD-NENs (mean 74%, range 34-99). All WD-NENs with Ki67 > 20% lacked abnormal p53 and loss of retinoblastoma 1 (Rb1) expression. In contrast, many PD-NENs expressed p53 (48%) and showed loss of Rb1 (86%). The 2- and 5-year disease-free survival rates in WD-NEN patients with Ki67 > 20% were lower than those of WD-NEN patients with Ki67 ≤20% (p < 0.01 for disease-free and overall survival). No statistical differences were detected between outcome of WD-NEN patients with Ki67 > 20% and those of PD-NEN. It is concluded that WD-NEN patients with Ki67 > 20% share the morphological and immunohistochemical features of WD-NEN patients with Ki67 ≤20%, but they have a worse prognosis, suggesting that this tumor group requires particular attention in future classifications and probably new therapeutic regimes.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Carcinoids; Ki67; Lung; Neuroendocrine neoplasms; WHO classification

Year:  2018        PMID: 30485860     DOI: 10.1159/000495806

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  15 in total

Review 1.  Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites.

Authors:  Silvia Uccella; Stefano La Rosa; Jasna Metovic; Deborah Marchiori; Jean-Yves Scoazec; Marco Volante; Ozgur Mete; Mauro Papotti
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

Review 2.  Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.

Authors:  Guido Rindi; Ozgur Mete; Silvia Uccella; Olca Basturk; Stefano La Rosa; Lodewijk A A Brosens; Shereen Ezzat; Wouter W de Herder; David S Klimstra; Mauro Papotti; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2022-03-16       Impact factor: 3.943

3.  Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma.

Authors:  Lirui Tang; Xiaoting Wei; Caili Li; Jie Dai; Xue Bai; Lili Mao; Zhihong Chi; Chuanliang Cui; Bin Lian; Bixia Tang; Yu Du; Xuan Wang; Yumei Lai; Xinan Sheng; Xieqiao Yan; Siming Li; Li Zhou; Yan Kong; Zhongwu Li; Lu Si; Jun Guo
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

4.  Risk factors of postoperative recurrence and potential candidate of adjuvant radiotherapy in lung adenosquamous carcinoma.

Authors:  Jianjiao Ni; Zhiqin Zheng; Juan Li; Yuan Li; Min Fan; Liang Liu
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

Review 5.  Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine/Non-neuroendocrine Neoplasms.

Authors:  Stefano La Rosa
Journal:  Endocr Pathol       Date:  2021-03-31       Impact factor: 3.943

6.  Two cases of lung neuroendocrine carcinoma with carcinoid morphology.

Authors:  Kenji Inafuku; Tomoyuki Yokose; Hiroyuki Ito; Daisuke Eriguchi; Joji Samejima; Takuya Nagashima; Haruhiko Nakayama; Masaki Suzuki; Kouzo Yamada; Munetaka Masuda
Journal:  Diagn Pathol       Date:  2019-09-12       Impact factor: 2.644

7.  Clinicopathological and immunohistochemical study of pulmonary neuroendocrine tumors - A single-institute experience.

Authors:  Uma Jyothi Swaroopa Pasala; Monalisa Hui; Shantveer G Uppin; N Narendra Kumar; K Bhaskar; G K Paramjyothi
Journal:  Lung India       Date:  2021 Mar-Apr

Review 8.  Molecular Pathology of Well-Differentiated Pulmonary and Thymic Neuroendocrine Tumors: What Do Pathologists Need to Know?

Authors:  Marco Volante; Ozgur Mete; Giuseppe Pelosi; Anja C Roden; Ernst Jan M Speel; Silvia Uccella
Journal:  Endocr Pathol       Date:  2021-02-27       Impact factor: 3.943

Review 9.  Classification of neuroendocrine neoplasms: lights and shadows.

Authors:  Stefano La Rosa; Silvia Uccella
Journal:  Rev Endocr Metab Disord       Date:  2020-11-09       Impact factor: 9.306

10.  Mesenchymal/non-epithelial mimickers of neuroendocrine neoplasms with a focus on fusion gene-associated and SWI/SNF-deficient tumors.

Authors:  Atsuko Kasajima; Björn Konukiewitz; Anna Melissa Schlitter; Wilko Weichert; Jan Hinrich Bräsen; Abbas Agaimy; Günter Klöppel
Journal:  Virchows Arch       Date:  2021-08-05       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.